Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2021 May 6;16(5):e0250607. doi: 10.1371/journal.pone.0250607

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction

Jason M Cota 1, Taylor M Benavides 1, John D Fields 1, Nathan Jansen 2, Anuradha Ganesan 3,4,5, Rhonda E Colombo 3,5,6, Jason M Blaylock 4, Ryan C Maves 5,7, Brian K Agan 3,5, Jason F Okulicz 2,*
Editor: Kwasi Torpey8
PMCID: PMC8101910  PMID: 33956843

Abstract

Objectives

We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs.

Methods

Male US Military HIV Natural History Study participants diagnosed with erectile dysfunction (ED) and having a PDE-5 inhibitor and potentially-interacting ART co-dispensed within 30 days were included. DDIs were defined according to criteria found in published guidelines and drug information resources. The primary outcome of interest was overall PDE-5 inhibitor-mediated DDI prevalence and episode duration. A secondary logistic regression analysis was performed on those with and without DDIs to identify factors associated with initial DDI episode.

Results

A total of 235 male participants with ED met inclusion criteria. The majority were White (50.6%) or African American (40.4%). Median age at medication co-dispensing (45 years), duration of HIV infection (14 years), and duration of ED (1 year) did not differ between the two groups (p>0.05 for all). PDE-5 inhibitors included sildenafil (n = 124), vardenafil (n = 99), and tadalafil (n = 14). ART regimens included RTV-boosted protease inhibitors (PIs) atazanavir (n = 83) or darunavir (n = 34), and COBI-boosted elvitegravir (n = 43). Potential DDIs occurred in 181 (77.0%) participants, of whom 122 (67.4%) had multiple DDI episodes. The median DDI duration was 8 (IQR 1–12) months. In multivariate analyses, non-statistically significant higher odds of DDIs were observed with RTV-boosted PIs or PI-based ART (OR 2.13, 95% CI 0.85–5.37) and in those with a diagnosis of major depressive disorder (OR 1.74, 95% CI 0.83–3.64).

Conclusions

PDE-5-mediated DDIs were observed in the majority of males with HIV infection on RTV- or COBI-boosted ART in our cohort. This study highlights the importance of assessing for DDIs among individuals on ART, especially those on boosted regimens.

Introduction

Men with human immunodeficiency virus (HIV) infection have a prevalence of erectile dysfunction (ED) that may be as high as 50% [1–3]. Phosphodiesterase type 5 (PDE-5) inhibitors such as sildenafil, tadalafil, and vardenafil are the drugs of choice for ED. Given that each of these PDE-5 inhibitors is primarily metabolized by the cytochrome P450 3A4 isoenzyme (CYP3A4), drug information databases (hiv-druginteractions.org) and antiretroviral therapy (ART) guidelines warn against co-administration with strong CYP3A4 inhibitors [4–7]. Protease inhibitors (PIs) and pharmacokinetic boosters such as ritonavir (RTV) and cobicistat (COBI) strongly inhibit CYP3A4 drug metabolism [6, 8, 9]. Therefore, resources recommend PDE-5 inhibitor dose reduction when initiating therapy with these potentially-interacting ART regimens or recommend lower starting PDE-5 inhibitor doses in patients already receiving this ART to avoid excessive PDE-5 inhibitor exposure. These recommendations are not only based on the theoretical mechanism of this CYP3A4-mediated interaction, but also on pharmacokinetic studies confirming substantially-elevated PDE-5 inhibitor levels with co-administration of PIs, RTV, or COBI. A four-fold increase in sildenafil systemic exposure results when given with PIs alone or RTV-boosted PIs. A greater than two-fold increase in sildenafil maximum serum concentrations was observed with COBI-boosted ART co-administration [10–12]. Excessive PDE-5 inhibitor exposure may result in clinically significant adverse effects such as hypotension, syncope, visual disturbances and/or priapism. PDE-5 inhibitor DDIs may be especially concerning because conflicting data suggest an increase in ED risk with prolonged HIV and PI use [3, 13, 14]. While several studies have documented the prevalence of clinically-significant DDIs in HIV-infected patients, none have specifically focused on potential interactions between PDE-5 inhibitors and ART [15–20]. We evaluated the prevalence and factors associated with PDE-5-mediated DDIs in men with ED and HIV infection on potentially-interacting ART.

Materials and methods

Study design

The US Military HIV Natural History (NHS) is a prospective observational cohort of active duty US military members and beneficiaries with HIV infection. Participants are evaluated approximately every 6–12 months with data collected for demographics, laboratory studies, medical diagnoses, and medications. All participants were ≥18 years of age and provided informed written consent for this IRB-approved study.

The NHS database was queried to identify male participants with a diagnosis of ED recorded between 2001 and 2016. Those with an ED diagnosis receiving a prescription for a PDE-5 inhibitor (sildenafil, vardenafil, or tadalafil) and a potentially-interacting ART regimen co-dispensed within 30 days were included. Potentially-interacting ART regimens included those that contained a PI, RTV, or COBI. Patient characteristics including age, race/ethnicity, initial HIV diagnosis date, and initial ED diagnosis date were collected. Race and ethnicity data were collected because previous studies have identified differences in the risk factors for and prevalence of severe erectile dysfunction [21]. While all patients were diagnosed with ED, collected comorbidities only included those previously identified as posing a high risk for severe ED such as cardiovascular disease, mental health disorders, diabetes, and smoking history. Comprehensive prescription information available for analysis included prescription fill dates, medication name, medication dose, and quantity dispensed. Additional medications known to affect CYP3A4 metabolism were captured if co-prescribed within 30-days of PDE-5 inhibitor dispensing date. These included 3A4 inhibitors (macrolides, azole antifungals, and statins) or those with 3A4 induction potential (rifamycins and anti-epileptic drugs).

Outcomes

The primary analysis sought to describe the prevalence and duration of DDIs between PDE-5 inhibitors and ART regimens containing a strong CYP3A4 inhibitor (PI, RTV, or COBI). A DDI was identified when a PDE-5 inhibitor was co-dispensed within 30 days of potentially-interacting ART using the following consistent definitions found across published guidelines and drug interaction programs [4–7]. For a patient with a past and current potentially-interacting ART prescription history who received a new first prescription for a PDE-5 inhibitor, a DDI was documented if: 1) the initial sildenafil dose exceeded 25 mg, 2) the initial vardenafil or tadalafil dose exceeded 2.5 mg, or 3) the tadalafil dose exceeded 10 mg at any time during the co-administration period. For those with a past and current PDE-5 inhibitor prescription history who received a new first prescription for a potentially-interacting ART regimen, a DDI was documented if the PDE-5 inhibitor dose was not discontinued or the dose was not reduced within 30 days of the new prescription for any PI-based ART (RTV-boosted or un-boosted) or COBI-boosted ART. The duration of a single discrete DDI episode was calculated by using the days supply listed on the prescription record. An additional DDI episode was captured if the aforementioned DDI definitions were met following a gap in prescription overlap greater than 90 days following the documented days supply.

Statistical analysis

Descriptive statistics were used to determine DDI prevalence and episode duration. In order to determine what factors were associated with the presence of a DDI, patients were divided into a DDI and a non-DDI cohort for logistic regression analysis. The following factors for a first DDI occurrence were evaluated using univariate logistic regression: age, race/ethnicity, time from HIV diagnosis to first DDI, time from ED diagnosis to first DDI, comorbidities that increase risk for more severe ED, first PDE-5 inhibitor prescription after RTV- or COBI-boosted ART, time from HIV diagnosis to first DDI, and time from ED diagnosis to first DDI. Factors with a p-value less than 0.2 in univariate analysis were included in a multivariate logistic regression model to identify associations associated with first DDI occurrence. Chi-square test was used to analyze categorical data. Continuous variables were assessed for normality using Shapiro-Wilk W test and Wilcoxon rank sum was used to compare the non-normally distributed data. A p-value less than 0.05 was considered statistically significant. Statistics were calculated using JMP® software (JMP Pro®, Version 14.1, SAS Institute Inc., Cary, NC, 1989–2019).

Results

Over the 16-year study period, 499 male NHS participants with an ED diagnosis were identified with a total of 137,632 prescriptions records available (Fig 1). Of the 35,918 ART prescriptions dispensed, 21.2% were for potentially-interacting ART (Fig 2). There were 7,590 PDE-5 inhibitor prescriptions dispensed with 52% for sildenafil, 40% for vardenafil, and 8% for tadalafil. Overall, 235 participants met criteria for study inclusion (Fig 1). The majority of participants were White (50.6%) with a median age of 45 (IQR 40–51) years at first co-dispensed PDE-5 inhibitor and ART. Participant characteristics were similar in the DDI and non-DDI groups (p>0.05 for all).

Fig 1.

Fig 1

Open in a new tab

Flow chart of participants screened for eligibility and included in study.

Fig 2. Number of PDE-5 inhibitor and potentially-interacting ART dispensed by year of study.

Fig 2

Open in a new tab

Outcomes

A total of 181 (77.0%) participants met the DDI definition (Table 1), of whom 122 (51.9%) had multiple DDI episodes. The median DDI duration was 8 (IQR 1–12) months. The majority of DDIs occurred in individuals already on PDE-5 inhibitors followed by the addition of ART (55.8%). Among initial DDI episodes, sildenafil doses were 100 mg (55.4%) and 50 mg (44.6%) whereas vardenafil doses were 10 mg (37.3%), 20 mg (32%), and 5 mg (30.7%). All 14 tadalafil prescriptions met criteria for a DDI when co-administered with potentially-interacting ART including 7, 6, and 1 prescriptions dispensed for 10 mg, 20 mg, and 5 mg doses, respectively. In two patients in the DDI cohort, simvastatin prescriptions were dispensed along with sildenafil and RTV-boosted regimens. As a CYP3A4 inhibitor, simvastatin would be expected to further exacerbate the PDE-5 inhibitor-RTV interaction. In both instances, the simvastatin prescription was discontinued and replaced by an alternative statin without CYP3A4 interaction potential. In one of these patients, one additional 90-day supply sildenafil prescriptions were dispensed. In the second patient, sildenafil was switched to vardenafil at an inappropriate dose of 10 mg. No patients in the non-DDI group received additional prescriptions known to affect CYP3A4 metabolism within 30 days of the co-dispensing of a PDE-5 inhibitor and potentially-interacting ART.

Table 1. Participant characteristics.

All (n = 235) DDI Group (n = 181) Non-DDI Group (n = 54) p-value
Median age at first DDI (years) 45 (40–51) 45 (40–51) 46 (41–51) 0.75
Race/ethnicity
 White 119 (50.6) 92 (50.8) 27 (50.0) 0.91
 African American 95 (40.4) 72 (39.8) 23 (42.6) 0.71
 Hispanic/Puerto Rican/Mexican 11 (4.7) 10 (5.5) 1 (1.9) 0.26
High risk co-morbidities
 Dyslipidemia 138 (58.7) 101 (55.8) 37 (68.5) 0.10
 Hypertension 72 (30.6) 56 (30.9) 16 (29.6) 0.85
 Major depressive disorder 68 (28.9) 57 (31.5) 11 (20.4) 0.11
 Generalized anxiety disorder 29 (12.3) 23 (12.7) 6 (11.1) 0.94
 Type 2 diabetes mellitus 19 (8.1) 16 (8.8) 3 (5.6) 0.62
 Tobacco use 30 (12.8) 23 (12.7) 7 (13.0) 0.85
 Two or more high risk co-morbidities 45 (19.1) 34 (18.8) 11 (20.4) 0.79
Median time from HIV diagnosis to first co-administration (years) 14 (8–19) 15 (9–18) 13 (6–21) 0.75
Median time from ED diagnosis to first co-administration (days) 379 (77–1622) 381 (89–1601) 360 (54–1694) 0.53
Median number of prescriptions at time of first co-administration 6 (4–15) 6 (4–15) 5 (4–15) 0.75
PDE-5 inhibitor started before potentially-interacting ART 134 (57.0) 101 (55.8) 33 (61.1) 0.49
PDE-5 inhibitor
sildenafil 124 (52.8) 92 (50.8) 32 (59.3) 0.28
vardenafil 99 (42.1) 77 (42.5) 22 (40.7) 0.81
tadalafil 14 (6.0) 14 (7.7) 0 (0) 0.12
Type of potentially-interacting ART
RTV-boosted regimens 162 (68.9) 125 (69.1) 37 (68.5) 0.94
atazanavir 83 (35.3) 68 (37.6) 15 (27.8) 0.19
darunavir 34 (14.5) 23 (12.7) 11 (20.4) 0.16
lopinavir 35 (14.9) 29 (16.0) 6 (11.1) 0.37
Cobicistat-boosted elvitegravir 43 (18.3) 29 (16.0) 14 (25.9) 0.10
Open in a new tab

Data expressed and number (%) or median (interquartile range)

DDI, drug-drug interaction; ED, erectile dysfunction; PDE-5, phosphodiesterase type 5; ART, antiretroviral therapy; RTV, ritonavir

Most DDIs occurred during the 2005–2008 period and involved RTV-boosted regimens (Fig 3). From 2012–2016, 72.7% of co-administrations of PDE-5 inhibitors and potentially-interacting ART met criteria for a DDI and increasingly involved the COBI-boosted elvitegravir regimen. PDE-5 inhibitor use peaked in 2015 with sildenafil representing 85% of PDE-5 inhibitors dispensed. RTV-boosted ART regimens peaked in 2013; the subsequent decline in RTV-boosted regimens was offset with an increase in COBI-boosted elvitegravir, which peaked during the last study year in 2016.

Fig 3. Potentially-interacting co-administrations per 4-year study period.

Fig 3

Open in a new tab

Among participant factors in univariate analyses that met criteria for inclusion in the multivariate model, age less than 45 and major depressive disorder were associated with increased odds of DDIs; whereas dyslipidemia was associated with decreased DDI risk (Table 2). There were four medication factors that were included in the multivariate analysis. Major depressive disorder and PI-based ART were associated with an increased DDI risk, but these factors did not reach statistical significance in multivariate analyses.

Table 2. Factors associated with PDE-5 inhibitor-mediated drug-drug interactions.

Univariate Logistic Regression OR 95% CI p-value
Participant Factors
Age <45 years at co-dispensing 1.55 0.83–2.89 0.16^
HIV >14 years at co-dispensing 1.33 0.72–2.44 0.36
ED >1 year at co-dispensing 1.05 0.58–1.94 0.86
Dyslipidemia 0.58 0.30–1.10 0.10^
Hypertension 1.06 0.55–2.07 0.85
Type 2 diabetes mellitus 1.65 0.46–5.88 0.44
Generalized anxiety disorder 2.00 0.67–6.03 0.22
Major depressive disorder 1.80 0.86–3.74 0.12^
Smoking history 0.75 0.24–1.55 0.25
>2 high-risk co-morbidities 0.90 0.42–1.93 0.80
African American 0.89 0.48–1.65 0.71
Medication Factors
Receipt of ART before PDE-5 inhibitor 1.25 0.67–2.32 0.49
Polypharmacy (>5 medications) 1.41 0.75–2.65 0.29
Any PI-based ART 1.83 0.38–3.79 0.10^
RTV-boosted atazanavir 1.56 0.80–3.05 0.19^
RTV-boosted darunavir 0.57 0.26–1.26 0.16^
RTV-boosted lopinavir 1.53 0.60–3.90 0.38
Sildenafil 0.71 0.38–1.32 0.18^
Vardenafil 1.08 0.58–2.00 0.81
Multivariate Logistic Regression OR 95% CI p-value
RTV-boosted atazanavir 1.07 0.47–2.44 0.87
Dyslipidemia 0.88 0.45–1.72 0.72
Sildenafil 0.87 0.46–1.72 0.69
Age<45 1.27 0.66–2.43 0.47
Major depressive disorder 1.74 0.83–3.64 0.14
RTV-boosted darunavir 0.48 0.19–1.23 0.13
RTV-boosted PI or PI-based ART 2.13 0.85–5.37 0.11
Open in a new tab

ART, antiretroviral therapy; PDE-5, phosphodiesterase type 5; RTV, ritonavir

^Univariate factors with a P<0.2 were included in the multivariate analysis

Discussion

A clinically-significant DDI involving ART may occur in approximately 1 in 3 to 4 persons living with HIV [7, 15, 17, 18]. This is the first study specifically addressing the prevalence of PDE-5 inhibitor-mediated DDIs in men with HIV infection. Studies confirming increased PDE-5 inhibitor concentrations with coadministration of PIs and pharmacokinetic boosters have been well documented since these ED treatment agents were first available for clinical use [12, 22–24]. At least two published case reports describe deaths associated with DDIs involving PDE-5 inhibitors and RTV-boosted ART [23, 25]. Such consequences make the recommendations for PDE-5 inhibitor dose reduction and slow up-titration essential when these ED agents are co-prescribed with strong CYP 3A4 inhibitors such as PIs, RTV, and COBI.

DDI management recommendations may be found in clinical practice guidelines and with use of dedicated online antiretroviral DDI checkers (hiv-druginteractions.org) [6, 7]. Despite this longstanding knowledge, PDE-5 inhibitor doses exceeded recommendations in more than 75% of HIV-infected men with ED receiving potentially-interacting ART in this study. In addition, approximately 60% of these patients received a PDE-5 inhibitor dose that was more than 4 to 8 times higher than the recommended starting dose. This would yield initial systemic exposures greater than 10 times higher than maximum recommended PDE-5 inhibitor doses when given alone.

It is unlikely that incomplete medical records contributed to the high frequency of DDIs in this cohort. Lack of clinician and patient awareness of potential interactions combined with underreporting of adverse consequences with this combination may be reasons why we observed such a high frequency of PDE-5 inhibitor-mediated DDIs. This is consistent with one study in which physicians were unable to correctly identify two-thirds of clinically-significant ART-mediated DDIs [26]. Similar findings from a separate study showed that DDIs were more likely to occur and be mismanaged when the interacting drug was prescribed by a provider not primarily involved in HIV care and ART prescribing [27]. Sildenafil is also indicated for pulmonary hypertension; co-administration of sildenafil and ritonavir is contraindicated in this setting. However, after review of the prescribed dosing regimens is it is unlikely that NHS participants were receiving sildenafil for pulmonary hypertension. Vardenafil prescriptions increased from 2006 to 2011; however, the percent of DDIs did not increase during this period when vardenafil was used along with potentially-interacting ART. PDE-5 inhibitor sharing and “recreational use” has been previously reported, but was not assessed in this study [28, 29].

Major depressive disorder and receipt of any PI-based ART were associated with an elevated, but non-statistically-significant increased risk of a PDE-5 inhibitor-mediated DDIs. Other studies have shown an increased risk of DDIs with use of PI-based or RTV-boosted ART regimens [15–18]. Patients were included in logistic regression models based on the first date of PDE-5 inhibitor and potentially-interacting ART co-administration. Using this approach and given the 2001 start date of this longitudinal database, a higher number of patients incorporated into the models were receiving any PI-based ART compared to newer COBI-boosted regimens, which were unavailable before 2012. However, more than 50% of patients included in our model had additional discrete DDIs with different PDE-5 inhibitors and/or newer ART regimens occur later in the study period. It is unclear how a different approach for model inclusion would have affected the detection of independent risk factors for DDIs.

Strengths

The strengths of this study include its large cohort size, large number of screened individuals, and the comprehensive prescription database maintained for participants enrolled in the US Military HIV Natural History Study.

Limitations

This study was limited by the retrospective design. Unfortunately, access to specific documented instances of hypotension, syncope, visual disturbances and/or priapism that may be associated with PDE-5 inhibitor-mediated DDIs were not available.

Conclusion

Drug interactions related to ED and ART therapy were identified in almost half of men with HIV infection receiving PDE-5 inhibitors for ED in our cohort. The high prevalence of co-administered ART and PDE-5 inhibitors with known interactions in this cohort of men with excellent access to healthcare highlights the need for ongoing multidisciplinary education on the importance of assessing for interactions when initiating or modifying medications in people with HIV on ART.

Acknowledgments

Disclaimer: The content of this publication is the sole responsibility of the authors and does not necessarily reflect the views or policies of the Uniformed Services University of the Health Sciences, Brooke Army Medical Center, the US Army Medical Department, the US Army Office of the Surgeon General, the Department of the Navy, the Department of the Army, the Department of the Air Force, the Department of Defense, or the US Government. Mention of trade name, commercial products, or organizations does not imply endorsement by the US Government.

The authors are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that ‘Copyright protection under this title is not available for any work of the United States Government.’ Title 17 U.S.C. 101 defines a United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person’s official duties.

Data Availability

Data for this study are available from the Infectious Disease Clinical Research Program (IDCRP), headquartered at the Uniformed Services University of the Health Sciences (USU), Department of Preventive Medicine and Biostatistics. The Informed Consent Document under which the HIV Natural History Study data were collected specifies that each use of the data will be reviewed by the Institutional Review Board. Furthermore, the data set may include Military Health System data collected under a Data Assurance Agreement that requires accounting for uses of the data. Data requests may be sent to: Address: 6270A Rockledge Drive, Suite 250, Bethesda, MD 20817. Email: contactus@idcrp.org.

Funding Statement

Support for this work (IDCRP-000-03) was provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Zona S, Guaraldi G, Luzi K, Beggi M, Santi D, Stentarelli C, et al. Erectile dysfunction is more common in young to middle-aged HIV-infected men than in HIV-uninfected men. J Sex Med 2012. July;9(7):1923–1930 10.1111/j.1743-6109.2012.02750.x [DOI] [PubMed] [Google Scholar]
  • 2.Santi D, Brigante G, Zona S, Guaraldi G, Rochira V. Male sexual dysfunction and HIV—a clinical perspective. Nat Rev Urol 2014. February;11(2):99–109 10.1038/nrurol.2013.314 [DOI] [PubMed] [Google Scholar]
  • 3.Luo L, Deng T, Zhao S, Li E, Liu L, Li F, et al. Association Between HIV Infection and Prevalence of Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med 2017. September;14(9):1125–1132 10.1016/j.jsxm.2017.07.001 [DOI] [PubMed] [Google Scholar]
  • 4.Lexicomp. Interactions. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. Accessed March 1, 2021
  • 5.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentsgl.pdf. Accessed March 1, 2021
  • 6.Rockstroh J, Bhagani S, Bruno R, García D, Journiac M, Lacombe K. European AIDS Clinical Society (EACS) Guidelines. Version 2012;6:2012 [Google Scholar]
  • 7.Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, et al. British HIV Association guidelines for the treatment of HIV†1†positive adults with antiretroviral therapy 2015. HIV medicine 2016;17:s2–s104 [DOI] [PubMed] [Google Scholar]
  • 8.Waters L, Ahmed N, Angus B, Boffito M, Bower M, Churchill D, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). 2016 [DOI] [PubMed] [Google Scholar]
  • 9.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services 2019 December 18,
  • 10.Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin Drug Investig 2008;28(8):479–485 10.2165/00044011-200828080-00002 [DOI] [PubMed] [Google Scholar]
  • 11.Pecora Fulco P, Patel B. Sildenafil Use for Pulmonary Artery Hypertension With a Cobicistat-Boosted Antiretroviral Regimen. Ann Pharmacother 2020. January 01;54(1):84–85 10.1177/1060028019865542 [DOI] [PubMed] [Google Scholar]
  • 12.Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999. October 22;13(15):101 10.1097/00002030-199910220-00001 [DOI] [PubMed] [Google Scholar]
  • 13.Fumaz CR, Ayestaran A, Perez-Alvarez N, Munoz-Moreno JA, Ferrer MJ, Negredo E, et al. Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. Am J Mens Health 2017. May;11(3):647–653 10.1177/1557988316669041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Colebunders R, Smets E, Verdonck K, Dreezen C. Sexual dysfunction with protease inhibitors. Lancet 1999. May 22;353(9166):1802–0 10.1016/S0140-6736(05)75908-0 [DOI] [PubMed] [Google Scholar]
  • 15.Iniesta-Navalon C, Franco-Miguel JJ, Gascon-Canovas JJ, Rentero-Redondo L. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach. HIV Med 2015. May;16(5):273–279 10.1111/hiv.12205 [DOI] [PubMed] [Google Scholar]
  • 16.Demessine L, Peyro-Saint-Paul L, Gardner EM, Ghosn J, Parienti JJ. Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France. Open Forum Infect Dis 2019. March 22;6(3):ofz051 10.1093/ofid/ofz051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007. October;27(10):1379–1386 10.1592/phco.27.10.1379 [DOI] [PubMed] [Google Scholar]
  • 18.Patel N, Abdelsayed S, Veve M, Miller CD. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother 2011. March;45(3):317–324 10.1345/aph.1P576 [DOI] [PubMed] [Google Scholar]
  • 19.Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, Patel N. Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. Ann Pharmacother 2017. May;51(5):365–372 10.1177/1060028016685115 [DOI] [PubMed] [Google Scholar]
  • 20.Sangiovanni RJ, Jakeman B, Nasiri M, Ruth L, Mahatme S, Patel N. Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy. AIDS Res Hum Retroviruses 2019. May;35(5):430–433 10.1089/AID.2018.0205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Smith JF, Caan BJ, Sternfeld B, Haque R, Quesenberry CP, Quinn VP, et al. Racial disparities in erectile dysfunction among participants in the California Men’s Health Study. J Sex Med 2009. December 01;6(12):3433–3439 10.1111/j.1743-6109.2009.01519.x [DOI] [PubMed] [Google Scholar]
  • 22.Nandwani R, Gourlay Y. Possible interaction between sildenafil and HIV combination therapy. Lancet 1999. March 06;353(9155):840–7 10.1016/S0140-6736(99)90041-7 [DOI] [PubMed] [Google Scholar]
  • 23.Hall MC, Ahmad S. Interaction between sildenafil and HIV-1 combination therapy. Lancet 1999. June 12;353(9169):2071–2072 10.1016/S0140-6736(05)77889-2 [DOI] [PubMed] [Google Scholar]
  • 24.Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000. August 01;50(2):99–107 10.1046/j.1365-2125.2000.00245.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kobayashi M, Takata Y, Goseki Y, Mizukami H, Hara S, Kuriiwa F, et al. A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 2015;179:421–423 10.1016/j.ijcard.2014.11.090 [DOI] [PubMed] [Google Scholar]
  • 26.Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, Carey PB, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clinical infectious diseases 2010;50(10):1419–1421 10.1086/652149 [DOI] [PubMed] [Google Scholar]
  • 27.Yiu P, Nguyen NN, Holodniy M. Clinically significant drug interactions in younger and older human immunodeficiency virus†positive patients receiving antiretroviral therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2011;31(5):480–489 [DOI] [PubMed] [Google Scholar]
  • 28.Hammoud MA, Jin F, Lea T, Maher L, Grierson J, Prestage G. Off-Label Use of Phosphodiesterase Type 5 Inhibitor Erectile Dysfunction Medication to Enhance Sex Among Gay and Bisexual Men in Australia: Results From the FLUX Study. J Sex Med 2017. June;14(6):774–784 10.1016/j.jsxm.2017.04.670 [DOI] [PubMed] [Google Scholar]
  • 29.Garin N, Zurita B, Velasco C, Feliu A, Gutierrez M, Masip M, et al. Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study. BMJ open 2017;7(1):e014105 10.1136/bmjopen-2016-014105 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Kwasi Torpey

11 Jan 2021

PONE-D-20-32474

High Frequency of Potential Phosphodiesterase Type 5 Inhibitor Drug Interactions in Males with HIV Infection and Erectile Dysfunction

PLOS ONE

Dear Dr. Okulicz,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 10th March 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Professor Kwasi Torpey, MD PhD MPH

Academic Editor

PLOS ONE

Additional Editor Comments:

The manuscript seeks to determine the prevalence of PDE-5 inhibitor drug drug interactions with antiretroviral therapy among men with erectile dysfunction. It is a retrospective cohort and applying a case control approach. There are major methodological concerns that needs to be addressed

1. Cases and controls were selected from the cohort. Cases were those who had DDIs as defined. The controls were those without the DDIs. Given that several factors may influence DDIs it is important for the authors to elaborately describe the cases and whether the controls were matched or unmatched?. Were there other co-morbid conditions and medications apart from ART? Were these matched? Case control design is used when a condition is rare/uncommon, however in this manuscript, the cases were actually more than the controls in >3:1.

2. Patient characteristics Page 5 Line 75 mentions co-morbidities however no information on the co-morbid conditions and the associated medications is provided in the results section. PDE 5 inhibitors is known to have interactions with not only ART but antibiotics like erythromycin, clarithromycin, antifungals, hypertensive medications, alcohol etc. There is no evidence presented on these associated factors in the manuscript.

3. Definition of DDI: The authors define a DDI was documented if: 1) the initial sildenafil dose exceeded 25 mg, 2) the initial vardenafil or tadalafil dose exceeded 2.5 mg, or 3) the tadalafil dose exceeded 10 mg at any time during the co-administration period. For those receiving a PDE-5 inhibitor who received a new first prescription for a potentially-interacting ART regimen, a DDI was identified if the PDE-5 inhibitor dose was not discontinued or the dose was not reduced within 30 days of the new prescription for any PI-based ART (RTV-boosted or un-boosted) or COBI-boosted ART. The scientific basis of this criteria is unclear. For example Sildenafil is given at a dose from 25mg to100mg to get the desirable effect. This may be be due to specific patient related factors or idiosyncratic. It is therefore problematic to assume that a dose of more than 25mg may be a potential case of DDI. The criteria of the dose not discontinued or reduced should be adequately explained

4. Additional DDI captured for gaps in medication should adequately elaborated Page 5 Line 89

Others

5. Description of the metabolic pathway/mechanism of action: The introduction must include why RTV or COBI is likely to increase the levels of PDE 5 inhibitors. Is it through the cytochrome P450 enzyme complex or another mechanism? This should be described.

6. Review of point 1 to 4 may influence the outcomes./results and subsequently the conclusion

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide a justification as to why participant ethnicity was studied as a variable. Furthermore, please note that according to our submission guidelines (http://journals.plos.org/plosone/s/submission-guidelines), outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. For example: “Caucasian” should be changed to “white” or “of [Western] European descent” (as appropriate).

Finally please provide a citation to the guidelines which were used to identify DDIs [line 81].

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study reported on drug-drug interaction (DDI) between phosphodiesterase type 5 (PDE-5) inhibitor and antiretroviral therapy (ART) in males with HIV infection and erectile dysfunction (ED) diagnosis. Generally, in this retrospective nature of the present study, causality cannot be inferred. They selected patients receiving both treatments among patients with HIV infection and ED, and defined those with high doses of PDE-5 inhibitor by a DDI group. Such patients may require its high doses due to disease severity or patient potential confounders, and I wonder why they have a conclusion that these patients met ED due to DDIs or they assessed other DDIs-related adverse effects such as hypotension and syncope. Additionally, how many patients taking both PDE-5 inhibitor and ART did not meet ED during the same period? Among these patients without ED, how many patients were considered as DDIs group, namely high doses of PDE-5 inhibitor? More detailed description regarding interaction between these treatments and adverse effects should be addressed. Otherwise, authors should downplay the interpretation of their results. I have following major concerns:

1. Patients needed higher doses of these disease modifying treatments might be likely to have sicker HIV conditions; hence this drug-drug interaction could be indispensable for managing such HIV patients. However, their description table lacked patient factors.

2. In multiple logistic regression model, all retained variables were medication factors (RTV-boosted atazanavir, Sildenafil, RTV-boosted, darunavir, RTV-boosted PI or PI-based ART). I think that these variables may be strongly correlated since patients with more disease severity require higher doses of these HIV-related treatments. Did you look at the multicollinearity of such medication variables?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Masatake Kobayashi

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Kwasi Torpey

12 Apr 2021

High Frequency of Potential Phosphodiesterase Type 5 Inhibitor Drug Interactions in Males with HIV Infection and Erectile Dysfunction

PONE-D-20-32474R1

Dear Dr. Okulicz,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Professor Kwasi Torpey, MD PhD MPH

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Manuscript significant improved and comments satisfactorily addressed

Reviewers' comments:

Acceptance letter

Kwasi Torpey

19 Apr 2021

PONE-D-20-32474R1

High Frequency of Potential Phosphodiesterase Type 5 Inhibitor Drug Interactions in Males with HIV Infection and Erectile Dysfunction

Dear Dr. Okulicz:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Kwasi Torpey

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers PDE5-ART DDI (2021-03-28).doc

    Click here for additional data file. (77KB, doc)

    Data Availability Statement

    Data for this study are available from the Infectious Disease Clinical Research Program (IDCRP), headquartered at the Uniformed Services University of the Health Sciences (USU), Department of Preventive Medicine and Biostatistics. The Informed Consent Document under which the HIV Natural History Study data were collected specifies that each use of the data will be reviewed by the Institutional Review Board. Furthermore, the data set may include Military Health System data collected under a Data Assurance Agreement that requires accounting for uses of the data. Data requests may be sent to: Address: 6270A Rockledge Drive, Suite 250, Bethesda, MD 20817. Email: contactus@idcrp.org.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES